SEC Company Response from PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Sep 28, 2015
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Sept. 28, 2015 · CIK: 0001472091 · Accession: 0001567619-15-001270
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206416
Letter
RE:
September 28, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Jeffrey P. Riedler, Assistant Director
Edge Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-206416
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Edge Therapeutics, Inc. (the “Registrant”) hereby requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 3:00 p.m. EDT on September 30, 2015, or as soon thereafter as practicable.
The Registrant acknowledges that:
1. should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
2. the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
3. the Registrant may not assert Staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
EDGE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm September 28, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jeffrey P. Riedler, Assistant Director RE: Edge Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-206416 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Edge Therapeutics, Inc. (the “Registrant”) hereby requests, subject to telephone confirmation, that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 3:00 p.m. EDT on September 30, 2015, or as soon thereafter as practicable. The Registrant acknowledges that: 1. should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; 2. the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and 3. the Registrant may not assert Staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, EDGE THERAPEUTICS, INC. /s/ Brian A. Leuthner Brian A. Leuthner President and Chief Executive Officer